FDA018 Antibody Drug Conjugate

FDA018抗体偶联剂

Report date: 2026/05/20 20:02:01

Base Information

Drug NameFDA018 Antibody Drug Conjugate
Drug Alias NameFDA018-ADCFDA-018-ADCF0024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SN-38 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTumor-associated calcium signal transducer 2 inhibitors
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFudan UniversityShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A